news
FDA peptide policy gains momentum; Whoop gains new CCO
The FDA's advisory committee meetings sparked legal discussion around peptides, with industry leaders weighing in. Meanwhile, WHOOP hired Glossier's former CEO as their Chief Commercial Officer. Also, the AI-powered robotic massage market is expanding, and skincare brand Prequel added new executives.
The FDA's advisory committee meetings sparked legal discussion around peptides, with industry leaders weighing in. Meanwhile, WHOOP hired Glossier's former CEO as their Chief Commercial Officer. Also, the AI-powered robotic massage market is expanding, and skincare brand Prequel added new executives.
The architecture take
The peptide chaos isn't going to last forever. Regulators are finally tuning into the noise around these compounds, especially as peptides edge closer to mainstream wellness. Expect an eventual clear-out of the wild west, narrowing the field to fewer, more reputable players. This isn't just about safety; it's about legitimizing a category currently running on grey-market energy. Also, Whoop bringing in a beauty-brand exec signals how much companies selling health data want to position themselves as lifestyle brands. They're not just selling metrics; they're selling an identity, and Glossier knows how to build that. This move tells you that the next battleground for wearables isn't just better tech, it's better branding and wider consumer adoption, merging health tech with aspirational living. This is where personalized data meets high-end influence.